Vivos Therapeutics, Inc. (VVOS)
After hours:
| Previous close | 1.9300 |
| Open | 1.9375 |
| Bid | 0.0000 x 0 |
| Ask | 3.5000 x 200 |
| Day's range | 1.9375 - 2.1000 |
| 52-week range | 1.9100 - 48.7900 |
| Volume | |
| Avg. volume | 168,206 |
| Market cap | 6.745M |
| Beta (5Y monthly) | 7.99 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Consolidated Water Comments on ISS and Glass Lewis Reports and Urges Stockholders to Vote “FOR” Re-Election of Its Highly Qualified Directors
Consolidated Water’s directors standing for re-election bring world-class backgrounds and relevant expertise to effectively oversee the Company’s activitiesGEORGE TOWN, Cayman Islands, May 20, 2024 (GLOBE NEWSWIRE) -- Consolidated Water Co. Ltd. (NASDAQ Global Select Market: CWCO), a leading designer, builder and operator of advanced water supply and treatment plants, today issued the following statement commenting on the reports issued by Institutional Shareholder Services (“ISS”) and Glass Lew
- GlobeNewswire
Vivos Therapeutics Reports First Quarter 2024 Financial Results and Provides Operational Update
Vivos Expanding its Revenue Generating InitiativesAs Operating Expenses Decrease 22%, Representing Seven Consecutive Quarters ofYear Over Year Improvement Due to Successful Cost Cutting Initiatives Management to Host Conference Call Today at 5:00 pm ET LITTLETON, Colo., May 14, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective propr
- GlobeNewswire
Vivos Therapeutics Schedules Release of First Quarter 2024 Financial Results and Conference Call
Call Scheduled for Today, Tuesday, May 14, 2024 at 5:00 pm ETLITTLETON, Colo., May 14, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults), today announced it plans to release its first quarter 2024 financi
